{
    "nct_id": "NCT00870311",
    "title": "Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients",
    "status": "COMPLETED",
    "last_update_time": "2009-03-25",
    "description_brief": "This study investigates the effects of Lithium treatment on signal transduction pathways, gene expression and brain neurochemistry and structure in patients with Bipolar disorder. It is hypothesized that specific changes in these markers will correlate with lithium treatment responsiveness.",
    "description_detailed": "This study investigates the effects of blinded lithium treatment longitudinally in patients with bipolar disorder. At baseline and at multiple time points following the initiation of lithium treatment over 4 or more weeks, measures of signal transduction pathways, gene expression and brain neurochemistry and structure were obtained. It is hypothesized that modulation of these measures will be predictive of lithium treatment responsiveness.",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "BASIC_SCIENCE",
    "results": null,
    "target_category": "N/A",
    "drug": [
        "Lithium (e.g., lithium carbonate)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial description studies Lithium treatment in manic (bipolar) patients, focusing on signal transduction, gene expression and brain myo\u2011inositol \u2014 i.e., effects in bipolar disorder rather than any Alzheimer\u2019s disease pathology. Lithium is a mood stabilizer used to treat acute mania and maintenance bipolar disorder. \ue200cite\ue202turn1search2\ue202turn1search9\ue201",
        "Act (extracted details): Drug: Lithium (commonly given as lithium carbonate). Mechanistic targets mentioned in the literature include inhibition of inositol monophosphatase (affecting myo\u2011inositol / phosphoinositide signaling) and effects on signal\u2011transduction pathways and gene expression (including proposed effects on GSK\u20113\u03b2 and downstream transcriptional programs). These mechanisms explain the study focus on signal transduction, gene expression and brain myo\u2011inositol levels. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search8\ue201",
        "Web search results supporting drug information (selected): \u2022 Lithium is prescribed to treat and prevent manic episodes in bipolar disorder (MedlinePlus). \ue200cite\ue202turn1search2\ue201 \u2022 Reviews describe lithium's actions on inositol metabolism (the inositol\u2011depletion hypothesis) and on signal transduction (e.g., IMPase inhibition, GSK\u20113\u03b2 effects). \ue200cite\ue202turn0search2\ue202turn0search3\ue201 \u2022 Preclinical and clinical studies show lithium alters myo\u2011inositol and related metabolites in brain. \ue200cite\ue202turn0search0\ue202turn0search1\ue201 \u2022 Comprehensive reviews summarize lithium\u2019s gene expression and neurotrophic effects relevant to long\u2011term therapeutic action. \ue200cite\ue202turn0search4\ue202turn1search11\ue201",
        "Reflect: The trial is not testing an Alzheimer\u2019s disease therapeutic (no anti\u2011amyloid or anti\u2011tau biologic/small molecule), nor is it described as a cognitive enhancer or an Alzheimer\u2011focused neuropsychiatric symptom study. Therefore it does not fit any of the four Alzheimer's disease\u2011focused categories (disease\u2011targeted biologic, disease\u2011targeted small molecule, cognitive enhancer, neuropsychiatric symptom improvement) and should be classified as 'N/A'. No ambiguity in the description suggests an alternative interpretation."
    ],
    "agent_type": "N/A",
    "explanation_agent": []
}